call on congress 2014 john marshall, treatment
DESCRIPTION
Treatment: It’s no longer “one size fits all” John Marshall, MD, Georgetown University Medical CenterTRANSCRIPT
Fighting a Smarter War On Colon Cancer:
John L. Marshall, MD Value as a new endpoint?
Tel: (202) 444-0275 Fax: (202) 444-1229
http://lombardi.georgetown.edu/GI
Stakeholder Mo-va-on
Stakeholders • FDA • CMS/Payers • NCI/CTEP • PhRMA • Community Onc • Academic Onc • Pa>ents
Priority/Agenda • Safety and Efficacy • Cost Control/Value • Cure Cancer • Markets, ROI • Efficient/Quality Care • Clinical Trial Accrual • Cure/Benefit/Altruism
Stakeholder Mo-va-on
Stakeholders • FDA • CMS/Payers • NCI/CTEP • PhRMA • Community Onc • Academic Onc • Pa>ents
Priority/Agenda • Safety and Efficacy • Cost Control/Value • Cure Cancer • Markets, ROI • Efficient/Quality Care • Clinical Trial Accrual • Cure/Benefit/Altruism
Worldwide Cancers Sta>s>cs
F. Bray et al, Lancet Oncol 2012; 13: 790–801 and h"p://www.cancer.org/aboutus/globalhealth. 2030 values are es>mated using projected incidence and mortality rates from 2008 to 2030 and weigh>ng for prevalence in developed compared to developing countries.
GI
2008
0
1000000
2000000
3000000
4000000
5000000
6000000
7000000
0
1000000
2000000
3000000
4000000
5000000
6000000
7000000
2030
Breast Prostate
Lung
Lung
Prostate
Breast
GI
Gastrointestinal (GI) Cancers Facts v GI cancers represent the most common and fatal cancers in the world
v 2009: 275,720 new diagnosis of GI Cancers and 135,830 deaths in the US alone
v Anal Cancer v Colorectal Cancer v Esophageal Cancer v Gallbladder Cancer v Liver Cancer v Pancreatic Cancer v Small Intestine Cancer v Stomach/Gastric Cancer
v No two cancers are alike and treatments must be selected based on an individual’s tumor characteristics, by personalized medicine
Breast Cancer Nation
Why Not Brown?
Value Safety and
Efficacy
Our Current Model of Colon Cancer
Antoni van Leeuwenhoek (1632-1723)
Invented the microscope around 1668
10
The view from 35,000 feet
Everything looks the same from up here
What can we predict?
Standard of Care
New Pa>ent
Diagnosis / staging
Standard Chemotherapy
Hope for the best
30% chance of any response
Cancer is driven by hyperactive or defective protein circuits The components of these circuits contain the drug targets
of the future.
Patient A Patient B
Each patient’s cancer is different. A drug that works for one patient may not work for another patient with the same cancer.
Ruesch Symposia:
• 2010 Biomarkers: Can we measure them? • 2011 Defining Value in Cancer • 2012 Clinical Research: Engaging the 97% • 2013 Molecular Profiling:Research/Prac>ce
Hypothesis
Prospec>ve incorpora>on of molecular profiling will
transform global cancer care
Personalized Medicine
New Pa>ent
Diagnosis / staging
HER2 ↑
TS ↓
TOP1 ↑
KRAS ↑ ERCC1 ↓
SPARC ↑
B-RAF ↑
PGP ↓
CURE?
Targeted Therapy
Personalized Therapy
↑ Response
Molecular-‐ Tailored Therapy
GI Cancer Pa>ents
Smart Centers
Profile All
Treatment Outcomes
Unified CRF/EMR
BioBank Team
Central Imaging
Central Consent
Data Cloud: Shared & IP Protected
Managed by DSM,
STATS HIPPA compliant,
Regulatory Review
Cancer Centers
Profilers
Pharma + Guidelines
Fundamental Shies In Cancer Care Yesterday • Consump>on • Individual Prac>ces • Rich Countries • Microscope • Safety and Efficacy • Large trials • 1.4 months • QOL • Pa>ent as a “Subject” • Chao>c Data Collec>on • Ins>tu>onal IRBs • Na>onal Approvals
Tomorrow • Outcomes • Healthcare Systems • All Countries • Gene Profile • Value • Small trials • “Substan>al Improvement” • Pa>ent Reported Outcomes • Pa>ent as a “Partner” • Standard Data Collec>on • Central/Na>onal IRBs • Global Approvals